Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TVB-2640 |
| Trade Name | |
| Synonyms | TVB2640|TVB 2640 |
| Drug Descriptions |
TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059, PMID: 31630414). |
| DrugClasses | FASN Inhibitor 5 |
| CAS Registry Number | 1399177-37-7 |
| NCIT ID | C118285 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Anastrozole + Trastuzumab + TVB-2640 | Anastrozole TVB-2640 Trastuzumab | 0 | 1 |
| Bevacizumab + TVB-2640 | Bevacizumab TVB-2640 | 0 | 1 |
| Enzalutamide + TVB-2640 | Enzalutamide TVB-2640 | 0 | 1 |
| Exemestane + Trastuzumab + TVB-2640 | Exemestane TVB-2640 Trastuzumab | 0 | 1 |
| Fulvestrant + Trastuzumab + TVB-2640 | Fulvestrant TVB-2640 Trastuzumab | 0 | 1 |
| Paclitaxel + Trastuzumab + TVB-2640 | Paclitaxel TVB-2640 Trastuzumab | 0 | 1 |
| Paclitaxel + TVB-2640 | Paclitaxel TVB-2640 | 0 | 0 |
| TVB-2640 | TVB-2640 | 0 | 3 |